Section He-C 402.21 - Educational Requirements(a) An ATC shall maintain and make available educational materials about cannabis and CIP and their use to qualifying patients, their designated caregivers, and their certifying providers.(b) Each ATC shall have an adequate supply of current educational materials available for distribution to registered qualifying patients and their designated caregivers, including any materials supplied by the department to be made available.(c) Educational materials shall be available for inspection by the department upon request.(d) The educational materials shall include, at a minimum, information about the following: (1) Strains of cannabis, routes of administration, and their different effects in order to assist in the selection of prepared cannabis;(2) How to achieve proper dosage for different routes of administration with an emphasis on using the smallest amount of cannabis possible to achieve the desired effect, and the impact of potency;(3) Substance use disorder information on tolerance, dependence, and withdrawal;(4) Substance misuse signs and symptoms;(5) Referral information to substance abuse treatment programs;(6) Possible side effects from the use of cannabis for therapeutic purposes;(7) The extent to which the ATC's cannabis and CIP meet or do not meet organic certification standards, other information concerning organic growing methods used by the ATC, and information concerning other methods used for cultivation and processing; and(8) The warning information required to be included on the label as per He-C 402.19(d) (1) j. and k. and (d) (2) h.(e) The materials in (d) (1) -(8) above shall be available in languages accessible to all patients served by the ATC including for the visually and hearing impaired.(f) ATCs shall offer tracking sheets to qualifying patients and their designated caregivers to keep track of the strains of cannabis used, the form of prepared cannabis used, and the effects of cannabis and CIP used.(g) ATCs shall keep a record for each qualifying patient, which includes: (1) The strains of cannabis dispensed, including potency; and(2) The form of prepared cannabis or CIP dispensed.(h) In addition to the information in (g) above, the ATC shall collect data from each qualifying patient who is willing to provide it regarding: (1) Strains used and routes of administration as they relate to qualifying conditions and symptoms;(2) Any side effects experienced;(3) Therapeutic effectiveness;(4) Overall satisfaction with the ATC and therapeutic cannabis program in general; and(5) Other efficacy and use surveys, as directed by the department, upon a qualifying patient's intake and at periodic and regular intervals.(i) The ATC shall develop and implement a policy designed to increase the participation of qualifying patients in the activities described in (h) above.(j) The data collected under (g) and (h) above shall be maintained using the qualifying patient's registry identification number and shall be made available to the department upon request.N.H. Admin. Code § He-C 402.21
Adopted byVolume XXXIV Number 50, Filed December 11, 2014, Proposed by #10731, Effective 11/25/2014.Amended by Volume XXXVIII Number 45, Filed November 8, 2018, Proposed by #12653, Effective 11/1/2018, Expires 11/1/2028.